ACE2 and COVID-19: Kragstrup and colleagues recently assessed ACE2, but not TMPRSS2, in hospitalized patients with COVID-19, and reported that higher baseline plasma ACE2 levels were significantly associated with poorer overall outcome (defined by worse WHOmax category) at 28 days [31].